Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

Inclusion Criteria: * 1\. A written informed consent form should be signed prior to any study-related procedures 2. Male or female, aged 18 or above. 3.Histologically confirmed IIIB-IV NSCLC. 4.Subjects have not received systemic treatment for locally advanced or metastatic non-small cell lung cancer. 5.The patients should be confirmed with KRAS G12C mutation and provide PD-L1 test result. 6.At least 1 measurable lesion (RECIST 1.1 criteria). 7.ECOG 0-1. 8. Good organ function includes: * Neutrophil count≥1.5×109/L, * Platelet count≥90×109/L, * Hemoglobin≥90g/L * Serum creatinine≤1.5×upper limit of normal (ULN), creatinine clearance≥50 mL/min (Cockcroft-Gault formula) * Total bilirubin≤1.5×ULN * AST and ALT≤2.5×ULN; for patients with liver metastasis, AST and ALT≤5×ULN, the investigator should determine whether they are enrolled * Normal coagulation function: INR and PT≤1.5×ULN ,APTT≤1.5×ULN * Urinary protein in routine urinalysis is less than 2+, or 24-hour urinary protein quantification is \< 1 g. 9\. Life expectancy is at least 3 months; 10.Negative pregnancy test at enrollment. Male or female subjects should commit to take adequate and effective contraceptive measures or abstain from sexual for the duration of study participation and within 3 months after the last dose of the study drug Exclusion Criteria: * 1.Patients received anti-tumor drug treatment or investigational drug treatment 3 years ago.2.Non-Small Cell Lung Cancer (NSCLC) with a history of other actiona…